←
Muzaffar Qazilbash20,414 posts
Muzaffar Qazilbash avatar

Muzaffar Qazilbash

@Transplant_Doc

Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own

◷ Joined July 2010▧ 369 Photos and videos
Samer Al Hadidi, MD,MS,FACP avatar
⟳ Muzaffar Qazilbash retweeted
Samer Al Hadidi, MD,MS,FACP@HadidiSamer·Nov 11

My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer 1⃣MonumenTAL-6: Tec+Tal and Tal+Pom vs EPd/PVd ➡️Phase III, RRMM after 1–4 prior lines, all exposed to anti-CD38 and lenalidomide (80% anti-CD38-refractory) ➡️n=838; median FU: 13.4 mo ➡️Tec+Tal improved PFS HR 0.11; 12-mo PFS 89% vs 30%) and OS (HR 0.38; 12-mo OS 91% vs 80%). Tal+Pom also better than control arm (PFS HR 0.27, OS HR 0.55). 🛑Grade 3/4 infections were 312% with Tec+Tal vs 25% with control (92% of patients needed IVIG), ICANS 6%, taste changes 76% and weight loss 41% (Only 6% stopped treatment for AEs) Time limited therapy with dual targeting in pts after anti-CD38/len failure

Post attachment
Saurabh Zanwar avatar
⟳ Muzaffar Qazilbash retweeted
Saurabh Zanwar@ZanwarSaurabh·Oct 27

Out now in @BloodCancerJnl Why does extramedullary myeloma (EMD) continue to have suboptimal responses to immune effector therapies? Using imaging mass cytometry, we mapped >100,000 cells from EMD and solitary plasmacytoma (SPM). The key finding: EMD TME shows marked heterogeneity characterised by immune exhaustion + spatial immune exclusion + regulatory niches. @myelomaMD @MJSteinhardt @Myeloma_mSMART nature.com/articles/s41408-0… 1/5 🧵

Neeraj Saini avatar
⟳ Muzaffar Qazilbash retweeted
Neeraj Saini@Scato_MM_logist·Oct 21

The answer is more nuanced than you suggest. Your case for PLEX rests on one premise — therapy takes 2–4 weeks to work and the kidney is getting damaged in the meantime. That was true in the MP era. It is not true in 2026.

Muzaffar Qazilbash avatar
Muzaffar Qazilbash@Transplant_Doc·Oct 20

Iceland monoclonal gammopathy screening study (iStopMM) -In 3541 MGUS patients with 4.5 years F/U, a 27-fold increase in smoldering MM detection but not active MM - No adverse psych impact of MGUS notification on patients #mmsm @SaemundurMD ascopubs.org/doi/10.1200/JCO…